Open AccessProgrammed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report
Author(s) -
Zhi-Yun Niu,
Li Sun,
Sicheng Wen,
Zheng-Rong Song,
Xing Liu,
Ying Wang,
Jianqiang Li,
Xuejun Zhang,
Fuxu Wang
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i10.2394
Subject(s) - medicine , refractory (planetary science) , chimeric antigen receptor , lymphoma , programmed cell death 1 , cancer research , antigen , receptor , oncology , immunotherapy , immunology , pd l1 , immune system , physics , astrobiology
Chimeric antigen receptor T cell (CART) therapy has benefited many refractory lymphoma patients, but some patients experience poor effects. Previous studies have shown that programmed cell death protein-1 (PD-1) inhibitors can improve and prolong the therapeutic effect of CAR-T cell treatment.